OUTLOOK SUMMARY DATA Risk Level Average Type of Stock Large-Blend Industry Med-Biomed/Gene Zacks Rank in Industry 7 of 167 Millennium Pharmaceuticals, Inc. is a drug discovery and development company. The company s key product is Velcade. Although Velcade s growth slowed down in 2006 due to stiff competition from Celgene s Revlimid and Thalidomide, sales reaccelerated in 2007. The recent encouraging phase III data for 1st lin treatment of MM could expand Velcade label and boost top line growth further in 2008 and beyond. The company also has a robust, interesting and early-stage pipeline which will contribute to revenue growth after 2009. As such, we upgrade Millennium shares from Hold to Buy with a price target of $18. visit also : about me at marketocracy ... my funds ... invest all way through blog